US10239846 — Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
Method of Use · Assigned to Celgene International II SARL · Expires 2030-11-15 · 4y remaining
What this patent protects
This patent protects methods of chiral synthesis and uses of compounds that selectively modulate the sphingosine 1 phosphate receptor.
USPTO Abstract
Compounds that selectively modulate the sphingosine 1 phosphate receptor are provided including compounds which modulate subtype 1 of the S1P receptor. Methods of chiral synthesis of such compounds are provided. Uses, methods of treatment or prevention and methods of preparing inventive compositions including inventive compounds are provided in connection with the treatment or prevention of diseases, malconditions, and disorders for which modulation of the sphingosine 1 phosphate receptor is medically indicated.
Drugs covered by this patent
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-3740 |
— | ozanimod-hydrochloride |
U-3740 |
— | ozanimod-hydrochloride |
U-3740 |
— | ozanimod-hydrochloride |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.